Business Wire

H.I.G.-CAPITAL

Share
H.I.G. Europe Exits Infinigate to Bridgepoint Following Successful European Expansion

H.I.G. Capital (“H.I.G.“), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell Infinigate (the “Company”) to Bridgepoint, an international alternative asset fund management group. H.I.G. acquired a majority stake in the Company in 2017. The transaction is subject to clearance by the relevant antitrust authorities.

Infinigate, founded in 1996, is a leading specialized value-added distributor (“VAD”) for cybersecurity and cloud solutions for the SME segment. The core of Infinigate’s business is software distribution – acting as a sales multiplicator between vendors and resellers, giving market access to disruptive vendors, and providing value-added services, such as technical support, trainings, and marketing support to vendors and resellers. Infinigate focuses on strongly growing cybersecurity and cloud segments and supports its multinational software vendors in their expansion throughout Europe by providing a network of more than 10,000 resellers.

With the support of H.I.G., the Company implemented a comprehensive European expansion strategy. Infinigate benefited from H.I.G.’s substantial expertise and extensive network in the technology sector, and from its experience in successfully implementing buy and build strategies. It acquired Dutch cyber security VAD Crypsys in 2017 to expand into the Benelux markets. It subsequently acquired acmeo, a German specialist distributor for the Managed Security Service Provider (“MSSP”) segment to expand into the cloud segment. During the past four years, Infinigate‘s management successfully managed to double the Company’s revenue. Today, the Company has more than 450 employees and is present in eleven European countries – including the DACH region, Benelux, France, the UK and the Nordic countries.

David Martinez, Chairman of the Board and founder of Infinigate, said: ”The close, trusting and successful cooperation with H.I.G. was key for Infinigate to continue its exceptional success story and to tap into additional markets on the continent. Together, we have successfully transformed Infinigate and established the Company as the European leader in the field of cybersecurity solutions. I would like to thank H.I.G. for their support these past few years and look forward to accompany the Company’s next chapter with Bridgepoint, our future investor.”

Klaus Schlichtherle, CEO of Infinigate, added: “Together with H.I.G., we have succeeded in further strengthening Infinigate’s position as a leading VAD in Europe and look forward to partnering with the team at Bridgepoint to continue with our growth strategy and take the business to the next level.”

Dr. Holger Kleingarn, Managing Director at H.I.G., commented: “We are delighted that we were able to support Infinigate on its successful growth trajectory towards a true European market leader. Infinigate demonstrates H.I.G.’s ability to develop companies through a sustainable combination of organic growth and acquisitions. Infinigate is perfectly positioned for further growth on a global scale, and we wish the management team continued success in the future.”

The parties have agreed not to disclose further details of the transaction.

About Infinigate

Infinigate was founded in 1996 as the first European distributor for internet technologies. Since the turn of the millennium, Infinigate has specialized exclusively in the distribution of cyber security solutions for sustainable protection of IT networks, servers, end devices, data and applications. With the acquisition of acmeo, the security competence of the group was extended to the cloud and MSSP (Managed Security Service Providing) business. As a true VAD, Infinigate focuses on innovative and explanation-intensive solutions for enterprises and provides manufacturers and partners (resellers, IT integrators, system houses, etc.) with a range of additional services in the areas of technology, marketing and sales. After several successful market entries and acquisitions, Infinigate intends to continue its geographic expansion strategy. Today, the Infinigate Group has more than 450 employees and is represented by subsidiaries in eleven European countries (Germany, Austria, Switzerland, UK, France, Netherlands, Belgium, Sweden, Norway, Denmark and Finland). Infinigate thus covers more than 80% of the Western European cyber security market potential and has established itself as the leading value-added distributor for cyber security in Europe.

About H.I.G. Capital

H.I.G. is a leading global alternative assets investment firm with over €35 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:

  1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
  3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com .

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye